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Abstract
Introduction: To date, there have been no reports on the prevalence of adrenal masses in type 2 diabetic
patients. The present study aimed to evaluate the prevalence of adrenal incidentaloma in type 2 diabetic patients
in Japan.
Subjects: We retrospectively evaluated the presence of adrenal masses using abdominal CT scans in 304 type 2
diabetic patients. In those with adrenal masses, we examined the hormone production capacity of the adrenal mass.
Results: Fourteen patients (4.6%) had an adrenal mass. Hormonal analysis identified one case as having subclinical
Cushing’s syndrome, two with primary aldosteronism. Eleven cases had non-functioning masses.
Discussion: The reported prevalence of adrenal incidentaloma in normal subjects is 0.6-4.0% in abdominal CT scan
series. Our results show a relatively high prevalence of adrenal tumors in diabetic patients. On the other hand, the
frequency of functional adenoma in diabetic patients is 21.4%, which is similar to that of normal subjects.
Conclusion: Although further studies are needed to evaluate the prevalence of adrenal tumors in diabetic patients,
our data suggest that evaluation of the presence of adrenal masses may be needed in patients with type 2
diabetes mellitus.
Introduction
The detection of clinically silent adrenal masses, known
as adrenal incidentalomas, has increased. This has
resulted from both technical improvements in abdominal
imaging devices and their increased usage. Typically,
these techniques include ultrasonography (US), com-
puted tomography (CT scan), and magnetic resonance
imaging [1]. As a result, adrenal incidentalomas have
become a relatively common finding in clinical practice
[2-4]. Many patients with adrenal incidentalomas display
altered glucose tolerance, insulin resistance and meta-
bolic syndrome [5,6], though there are no reports on the
frequency of adrenal masses in type 2 diabetic patients in
Japan. Therefore, we investigated the presence of adrenal
tumors in Japanese type 2 diabetic patients.
Materials and methods
Individuals, presenting to outpatient clinics of the Depart-
ment of Diabetes, Metabolism and Endocrinology at Toho
University Hospital, the Department of Internal Medicine
at the Saiseikai Kanagawa-ken Hospital or the Kawasaki
Social Insurance Hospital between December 2004 and
November 2006, were selected for a retrospective study on
the prevalence of adrenal incidentaloma in type 2 diabetic
patients. In total, 304 Japanese type 2 diabetic patients
(123 women and 181 men; mean age, 61.9 ± 13.2 years
[range, 22-89]) were examined in this study. All patients
underwent careful clinical examination and none displayed
specific symptoms of hypercortisolism. Subjects with a his-
tory or clinical evidence of significant secondary hyperten-
sion, malignant and/or adrenal tumors, and exogenous
glucocorticoid intake were excluded. The main character-
istics of the diabetic patients with and without adrenal
masses are shown in Table 1.
Abdominal CT scan and US were performed to screen
for tumorous lesions including malignant disorders at
the time that these diabetic patients presented to our
outpatient clinics. Only abdominal CT scan data were
selected for this study, because the resolution of CT
scans is better than that of US. The imaging characteris-
tics used for the detection of adrenal masses were
recorded on the basis of both of a radiologist’sa n da n
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any medium, provided the original work is properly cited.endocrinologist’s description. The diagnosis of cortical
adenoma was based on the following CT scan criteria:
size >10 mm, smooth margin and homogeneous with a
relatively low CT density (≤10 Hounsfield units [HU] on
unenhanced CT scan). A non-contrast CT scan attenua-
t i o nv a l u eo f1 0H Ui sas a f ec u t - o f fv a l u ef o rd i f f e r e n -
tiating adrenal adenomas from non-adenomas [7,8].
The following hormonal determinations were per-
formed in patients with adrenal masses in order to diag-
nose the presence of functional adenomas: levels of
plasma adrenocorticotropic hormone (ACTH), and
serum cortisol, aldosterone, dehydroepiandrosterone-sul-
fate (DHEA-S) and catecholamines, and plasma renin
activity (PRA). Serum cortisol levels were evaluated after
an overnight 1 or 8 mg dexamethasone suppression test
for the diagnosis of subclinical Cushing’ss y n d r o m e
(SCS). When serum cortisol remained above 3.0 μg/dL
using 1 mg dexamethasone or 1 μg/dL using 8 mg dexa-
methasone, this indicated insufficient suppression. This
criterion is recommended by the ‘Disorders of Adrenal
Hormones’ Research Committee of the Japanese Minis-
try of Health and Welfare [9]. The diagnosis of SCS was
made according to the criteria established in the same
report [9]. Primary aldosteronism (PA) was diagnosed
using the 40 mg furosemide-upright test and the 50 mg
captopril-loading test in patients with an aldosterone-
renin ratio (ARR) of more than 200. Patients with a
PRA level below 1.0 ng/mL/hr 120 minutes after furose-
mide injection and ARR of more than 300 at 90 minutes
after captopril administration were diagnosed as having
PA [10-12].
Samples used for measuring hormone levels were all
collected at 9 am and centrifuged at 4°C, and plasma
and serum were then separated and stored at -20°C
until the assays. Plasma ACTH was measured using a
commercially available ECLIA kit (Roche Diagnostics,
Tokyo, Japan). Serum cortisol and DHEA-S (Diagnostic
Products Corp., Tokyo, Japan), and aldosterone (Dinabot
Corp., Osaka, Japan) were measured with commercially
available RIA kits. Plasma renin activity was determined
by RIA kit (TFB, INC., Tokyo, Japan). Catecholamines,
adrenaline and noradrenaline were measured by the spe-
cific HPLC method [13].
Measurements for diabetic patients with and without
adrenal masses were compared using Student’s t test,
and P < 0.05 were regarded as significant. Data are
expressed as means ± SD.
Results
An analysis of the age and gender distribution of diabetic
patients with adrenal masses showed that they do not dif-
fer from diabetic patients without such masses. We
determined that there were no significant differences in
height, weight, body mass index and known duration of
diabetes between these groups. Nor was any significant
difference observed in diabetic parameters, such as fast-
ing blood glucose, glycosylated hemoglobin, urinary C-
peptide and urinary albumin excretion (Table 1).
Fourteen of the 304 type 2 diabetic patients who were
analyzed by CT scan (4.6%; 7 women, 7 men; mean age
58.7 ± 14.0) were found to harbor an adrenal incidenta-
loma. Adrenal masses were found in the right adrenal
gland in seven cases (50.0%), in the left adrenal gland in
six (42.9%), and bilaterally in one (7.1%). The mean
adrenal mass size was 16.3 ± 5.6 mm (maximum and
minimum sizes were 26.0 and 10.0 mm, respectively).
In these patients, the mean diameter was 14.3 ± 4.1 mm
for non-functioning and 24.3 ± 2.9 mm for functioning
masses (P < 0.005). Morphologically, all adrenal masses
were homogenous with an attenuation value below 10
HU on unenhanced CT scan (mean value, 7.3 ± 2.9;
range, 1-10), with neither cysts nor calcification. None
of the patients presented with clinical features suggest-
ing any overt adrenal hyper-function (Table 2).
The levels of plasma ACTH (33.6 ± 22.5 pg/mL) and
serum cortisol (14.9 ± 6.4 μg/dL) in patients with adre-
nal masses were within normal ranges. Serum cortisol
levels were suppressed after the administration of 1 mg
Table 1 General data for the 304 patients with type 2 diabetes mellitus
Diabetic patients (n = 304) without adrenal mass (n = 290) with adrenal mass (n = 14)
Age 62.1 ± 13.1 58.7 ± 14.0
Sex (Female/Male) 116/174 (40.0%/60.0%) 7/7 (50.0%/50.0%)
Height (cm) 160.7 ± 9.6 162.3 ± 11.6
Weight (kg) 64.8 ± 16.5 72.7 ± 21.7
Body mass index (kg/m
2) 24.9 ± 5.6 27.5 ± 7.1
Blood Glucose (mg/dL) 221.1 ± 137.5 168.2 ± 59.8
Glycosylated Hemoglobin (%) 8.5 ± 6.6 7.7 ± 1.4
Urinary C-peptide (μg/day) 46.3 ± 41.2 41.3 ± 15.2
Urinary albumin excretion (mg/g·Cr) 317.7 ± 870.0 437.4 ± 1256.7
Known duration of diabetes (years) 10.3 ± 9.9 12.1 ± 12.1
Data are expressed as means ± SD, number or %.
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Page 2 of 5of dexamethasone in cases 1 to 13 but not in case 14 with
either 1 mg or 8 mg dexamethasone. The DHEA-S levels
were within the age-matched normal range in all but case
14. The aldosterone and PRA levels were 89.9 ± 45.6 pg/
mL and 1.1 ± 0.5 ng/mL/hr, respectively. In cases 12 and
13, the ARR was >200, and the furosemide-upright test
and captopril loading test were positive but in all other
cases the ARR values were <200. We thus diagnosed
cases 12 and 13 as having PA, case 14 as having SCS
only, and the other 11 cases as having non-functioning
adrenal tumors. In both patients with PA, normalization
of the ARR and blood pressure decreases were observed
after adrenalectomy. However, the SCS case was not trea-
ted surgically, because this patient refused adrenalect-
omy. Since adrenaline and noradrenaline levels were
within normal range (the total of adrenaline plus nora-
drenaline was <500 pg/mL), the possibility of pheochro-
mocytoma was excluded (data not shown).
Discussion
The mean prevalence of adrenal incidentalomas as
determined in autopsy series is 1.9-8.7% [14-16],
whereas in CT scan series published in the period from
1982 to 1994, it was 0.6-1.5% [14,15,17-19]. Recently,
Bovio et al reported that the prevalence of adrenal
masses on abdominal CT scans was 4.4% in Italian
patients with high risk of lung cancer, and that of
benign adrenal masses was 4.2% [20]. In our study, we
observed a relatively high prevalence of adrenal masses
(4.6%) in Japanese type 2 diabetic patients. Some reports
have shown that patients with adrenal incidentaloma
have insulin resistance and metabolic syndrome,
although the majority of these masses do not show hor-
monal hyper-secretion [5,6,21-23]. Terzolo et al demon-
strated that non-functioning adenomas have different
patterns of steroid secretion [21], and subtle autono-
mous cortisol secretion might be one of the reasons for
the high prevalence of adrenal incidentaloma in type 2
diabetic patients. In addition, recent advances in CT
scan technology could be expected to lead to an
increased rate of adrenal incidentaloma discovery.
In approximately 70% of cases, adrenal incidentalomas
are non-functional adenomas [24]. Investigations of
adrenal incidentalomas in Japan have shown the preva-
lence of functional adrenal adenoma to be approxi-
mately 50% [25]. The frequencies of cortisol-producing
Table 2 Characteristics for the 14 patients with adrenal lesions
ACTH
(pg/mL)
COR
(mg/
dL)
DST PAC
(pg/mL)
PRA
(ng/mL/
hr)
Confirm
exam for
PA
Laterality Size HU BP Diag
1m g 8m g
COR COR Furo-up
(PRA)
Capt
(ARR)
systolic diastolic
Normal
range
7.2 ~
63.3
4.0 ~
18.3
< 3.0 < 1.0 29.9 ~
159
0.3 ~ 2.9 < 2.0 < 200
1 25.4 8.5 0.8 63.5 2.3 Right 10 5 128 76 NF
2 58.3 20.7 2.9 33.3 1.0 Left 10 10 132 80 NF
3 34.8 10.1 < 1.0 88.7 1.4 Left 13 8 130 82 NF
4 25.1 19.3 1.6 67.5 0.9 Right 19 10 134 84 NF
5 80.7 21.7 1.9 104 0.8 Left 10 9 138 88 NF
6 20.6 9.9 2.6 68.7 1.2 Left 16 5 140 80 NF
7 18.8 21.6 2.9 75 1.0 bilateral 21/20 6 130 78 NF
8 77 25.1 < 1.0 69.5 1.1 Right 12 4 134 80 NF
9 29.8 9.2 1.6 83.6 1.7 Right 14 1 148 84 NF
10 28.6 9.5 2.4 60.8 0.9 Left 10 5 140 90 NF
11 31.4 14.2 2.6 100.8 1.0 Right 16 10 126 74 NF
12 7.7 11.7 2.3 227 0.9 0.9 312.0 Right 26 9 140 88 PA
13 16.2 5.5 2.2 128.6 0.2 0.2 416.7 Right 26 10 142 86 PA
14 16.1 21.4 5.3 3.0 88 0.8 Left 21 10 138 84 SCS
Mean ±
SD
33.6 ±
22.5
14.9 ±
6.4
2.4 ±
1.1
89.9 ±
45.6
1.1 ± 0.5 Right:7
Left:6
Bilateral:1
16.3 ±
5.6
7.3 ±
2.9
136.6 ±
6.4
82.4 ±
4.7
NF:11
PA:2
SCS:1
Cases 1 to 11 have non-functional adrenal masses, and 12 to 14 have functional adrenal masses including SCS and PA. Data are expressed as means ± SD or
number.
ACTH: adrenocorticotropic hormone, COR: corisol, PAC: plasma aldosterone concentration, PRA: plasma rennin activity, DST: dexamethasone suppression test,
Furo-upright: frosemide-upright test, Capt: Captopril loading test, HU: Hounsfield unit, NF: non-functional mass, SCS: subclinical Cushing’s syndrome, PA: primary
aldosteronism
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populations are 6.0-11.7% and 3.0-4.3%, respectively
[25,26]. Herein, a functional adrenal mass in type 2 dia-
betic patients with adrenal incidentalomas was seen in
three out of 14 cases (21.4%), with one case of SCS
(7.1%) and two of PA (14.3%). It should be noted that
the small number of functional tumors identified in this
report may have limited the identification of other types
of adrenal functional tumors.
The prevalence of subclinical hyper-cortisolism of
adrenal origin in diabetic patients is reported to be 1.1-
7.1% [27-29]. In the present study, the prevalence of
adrenal SCS was only 0.7% in type 2 diabetic patients.
This may be one reason for the low prevalence of adre-
nal SCS, i.e., that the Japanese diagnostic criteria for
SCS were used in this study. The cut-off value of the 1
mg dexamethasone suppression test in the Japanese
diagnostic criteria was high, 3.0 μg/dL, in comparison
with the diagnostic criteria of the Endocrine Society, for
which the cut-off value after 1 mg dexamethasone
administration is 1.8 μg/dL [30]. Although levels of cor-
tisol exceeded 1.8 μg/dL after administration of 1 mg
dexamethasone in cases 2, 5, 6, 7, 10 and 11, DHEA-S
levels were normal. Therefore, the possibility of diabetes
seems low in these cases. On the other hand, in case 14
diagnosed with SCS, the DHEA-S level was suppressed
with 8.0 μg/dL.
To our knowledge, there are no reports indicating that
diabetes induces adrenal incidentaloma, SCS or PA. On
the other hand, the pathogenesis of diabetes mellitus is
reportedly associated with PA related to impaired insulin
secretion due to hypokalemia [31]. Colussi et al demon-
strated a direct relationship between aldosterone, insulin
resistance and hyperinsulinemia [32,33]. Overproduction
of cortisol is reportedly associated with insulin resistance
[34], and higher cortisol concentrations are also related
to reduced insulin secretion [35]. Therefore, in patients
with SCS and PA, diabetes mellitus may develop.
In this study, adrenal masses were found at the same
frequency on the right (50.0%) and left sides (42.9%),
whereas bilateral masses were detected in one (7.1%) of
our cases. A similar lateral distribution of adrenal
masses has been reported in CT scan series [25,36,37].
An evaluation of the lateral distribution of adrenal
masses using abdominal US showed right predominance
[24], whereas Bovio et al reported that masses were
detected more frequently in the left adrenal gland [20].
Previously, the sole predictor of the risk of adrenocorti-
cal carcinoma was mass size [25,36]. The incidence of
malignant adrenal tumors is significantly higher in cases
where the size of the masses is greater than 40-50 mm
[24,25]. The mean diameter of adrenal masses discovered
on CT scans was 16.3 ± 5.6 mm, ranging from 10.0 to 26.0
mm, with no malignancy observed in any of our cases. In
addition, these data confirm previous results and show the
mean size of functional masses to be significantly higher
than that of non-functioning masses [37-39].
Conclusion
The frequency of functional adrenal masses in Japanese
type 2 diabetic patients with such masses was almost
the same as that in normal subjects, though a relatively
high prevalence of adrenal masses was found in our
study. Although further studies are needed to evaluate
the frequency of adrenal masses in Japanese type 2 dia-
betic patients, our data suggest that evaluation for the
presence of adrenal masses may be needed in patients
with type 2 diabetes mellitus.
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